argenx SE
ISIN: NL0010832176 | Ticker: 1AE | LEI: 7245009C5FZE6G9ODQ71
Country: Belgium
argenx SE is a biotechnology company that focuses on developing immunology solutions to help patients with autoimmune diseases. The company strives to co-create innovative therapies that will make a life-changing difference for patients. Arganx SE is committed to leveraging the power of the immune system to develop therapeutic solutions for some of the toughest autoimmune diseases out there. The company has a team of highly committed professionals with expertise in medical writing, clinical development, regulatory affairs, and other related fields who work closely to drive innovation and create solutions to help patients reach their full potential.
Year founded2008
Served areaWorldwide
HeadquartersLaarderhoogtweg 25, 1101 Amsterdam – Belgium
| Line item in (usd) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 1,610,215,000.00 | 2,279,407,000.00 | 2,850,274,000.00 | 3,134,261,000.00 |
| Noncurrent Assets | N/A | 67,540,000.00 | 222,406,000.00 | 307,303,000.00 | 360,064,000.00 |
| Property Plant And Equipment | N/A | 9,175,000.00 | 11,582,000.00 | 15,844,000.00 | 16,234,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 45,117,000.00 | 167,344,000.00 | 171,684,000.00 | 174,901,000.00 |
| Investments In Subsidiaries Joint Ventures And Associates | N/A | N/A | 0.00 | 0.00 | 1,323,000.00 |
| Deferred Tax Assets | N/A | 0.00 | 15,038,000.00 | 32,191,000.00 | 79,222,000.00 |
| Other Noncurrent Assets | N/A | 3,624,000.00 | 7,816,000.00 | 54,876,000.00 | 40,894,000.00 |
| Current Assets | N/A | 1,542,675,000.00 | 2,057,001,000.00 | 2,542,971,000.00 | 2,774,197,000.00 |
| Inventories | N/A | 0.00 | 25,195,000.00 | 109,076,000.00 | 228,353,000.00 |
| Trade And Other Current Receivables | N/A | 31,585,000.00 | 6,978,000.00 | 38,221,000.00 | 275,697,000.00 |
| Current Prepaid Expenses | N/A | 10,136,000.00 | 27,913,000.00 | 58,946,000.00 | 76,022,000.00 |
| Cash and cash equivalents | 321,791,000.00 | 372,162,000.00 | 1,216,803,000.00 | 1,334,676,000.00 | 800,740,000.00 |
| Equity And Liabilities | N/A | 1,610,215,000.00 | 2,279,407,000.00 | 2,850,274,000.00 | 3,134,261,000.00 |
| Equity | 616,462,000.00 | 1,180,409,000.00 | 1,674,051,000.00 | 2,534,224,000.00 | 2,813,699,000.00 |
| Issued Capital | N/A | 5,209,000.00 | 5,744,000.00 | 6,233,000.00 | 6,640,000.00 |
| Retained Earnings | N/A | -383,477,000.00 | -991,932,000.00 | -1,400,197,000.00 | -2,109,791,000.00 |
| Share Premium | N/A | 1,505,641,000.00 | 2,339,033,000.00 | 3,462,775,000.00 | 4,309,880,000.00 |
| Liabilities | N/A | 429,806,000.00 | 605,356,000.00 | 316,050,000.00 | 320,562,000.00 |
| Noncurrent Liabilities | N/A | 250,110,000.00 | 276,863,000.00 | 14,811,000.00 | 18,285,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 72,000.00 | 156,000.00 | 417,000.00 | 870,000.00 |
| Deferred Tax Liabilities | N/A | 0.00 | 1,487,000.00 | 6,438,000.00 | 8,406,000.00 |
| Current Liabilities | N/A | 179,696,000.00 | 328,493,000.00 | 301,239,000.00 | 302,277,000.00 |
| Trade And Other Current Payables | N/A | 95,827,000.00 | 275,192,000.00 | 293,415,000.00 | 295,679,000.00 |
| Current Tax Liabilities Current | N/A | 386,000.00 | 3,497,000.00 | 4,315,000.00 | 3,181,000.00 |
| Line item in (usd) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 78,462,000.00 | 41,243,000.00 | 497,277,000.00 | N/A |
| Revenue From Sale Of Goods | N/A | 0.00 | 0.00 | 400,720,000.00 |
| Profit Loss From Operating Activities | -198,892,000.00 | -477,617,000.00 | -348,746,000.00 | -720,341,000.00 |
| Finance Income | N/A | 6,459,000.00 | 3,633,000.00 | 27,665,000.00 |
| Finance Costs | N/A | 7,960,000.00 | 4,578,000.00 | 3,906,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | N/A | 0.00 | 0.00 | -677,000.00 |
| Profit Loss Before Tax | -175,919,000.00 | -605,352,000.00 | -399,743,000.00 | -729,314,000.00 |
| Income Tax Expense Continuing Operations | 5,289,000.00 | 3,103,000.00 | 8,522,000.00 | -19,720,000.00 |
| Profit (loss) | -181,208,000.00 | -608,455,000.00 | -408,265,000.00 | -709,594,000.00 |
| Profit Loss Attributable To Owners Of Parent | -181,208,000.00 | -608,455,000.00 | -408,265,000.00 | -709,594,000.00 |
| Line item in (usd) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | N/A | -181,208,000.00 | -608,455,000.00 | -408,265,000.00 | -709,594,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 0.00 | -23,852,000.00 | -83,880,000.00 | -119,277,000.00 |
| Adjustments For Provisions | N/A | 64,000.00 | 76,000.00 | 260,000.00 | 459,000.00 |
| Adjustments For Sharebased Payments | N/A | 44,236,000.00 | 96,932,000.00 | 179,366,000.00 | 157,026,000.00 |
| Adjustments For Fair Value Gains Losses | N/A | -1,214,000.00 | -2,951,000.00 | -11,152,000.00 | -4,256,000.00 |
| Other Adjustments For Noncash Items | N/A | 0.00 | 0.00 | -75,000,000.00 | 0.00 |
| Cash Flows From Used In Operations | N/A | 156,645,000.00 | -395,272,000.00 | -590,356,000.00 | -837,815,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 139,000.00 | 401,000.00 | 684,000.00 | 851,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 4,876,000.00 | 2,791,000.00 | 15,772,000.00 | 24,141,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 151,630,000.00 | -398,463,000.00 | -606,812,000.00 | -862,807,000.00 |
| Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities | N/A | N/A | 0.00 | 0.00 | 2,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 1,796,000.00 | 1,068,000.00 | 3,623,000.00 | 837,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 44,939,000.00 | 4,071,000.00 | 117,811,000.00 | 102,986,000.00 |
| Interest Received Classified As Investing Activities | N/A | 6,122,000.00 | 7,962,000.00 | 2,603,000.00 | 13,146,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -833,267,000.00 | 344,692,000.00 | -347,070,000.00 | -461,184,000.00 |
| Proceeds From Issuing Shares | N/A | 755,641,000.00 | 813,186,000.00 | 1,091,326,000.00 | 760,953,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,515,000.00 | 2,550,000.00 | 3,855,000.00 | 4,165,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 733,726,000.00 | 833,003,000.00 | 1,121,342,000.00 | 843,757,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 52,088,000.00 | 779,232,000.00 | 167,460,000.00 | -480,234,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -1,717,000.00 | 65,409,000.00 | -49,587,000.00 | -53,702,000.00 |
| Cash and cash equivalents | 321,791,000.00 | 372,162,000.00 | 1,216,803,000.00 | 1,334,676,000.00 | 800,740,000.00 |
Please note that some sums might not add up.
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| Jefferies Financial Group Inc. | 0.55% | 24.01.24 |
| Total | 0.55% |
NL0010832176
LEI7245009C5FZE6G9ODQ71
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryBEL20
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.